Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (2) Cakmak-Görür, Nese Dr. (1) Daniel, Peter Prof. Dr. (2) Dhamodaran, Arunraj (1) Dyck, Lydia Dr. (1) Kammertöns, Thomas Dr. (9) Kopp, Joachim Dr. (2) Kühn, Ralf Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (3) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Mertins, Philipp Dr. (1) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (4) Poncette, Lucia (2) Popp, Oliver Dr. (1) Rhein, Simone Dr. (1) Richter, Matthias (1) Schütz, Anja Dr. (1) Siffrin, Volker (1) Sporbert, Anje Dr. (1) Uckert, Wolfgang Prof. Dr. (5) Willimsky, Gerald Dr. (5) (-) Blankenstein, Thomas Prof. Dr. (26) Advanced Light Microscopy (1) Animal Phenotyping (1) Bioinformatics and Omics Data Science (3) Biologie maligner Lymphome (24) Entwicklung Mechanismus-basierter Krebstherapien (1) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Genom-Editierung & Krankheitsmodelle (1) Immunregulation und Krebs (2) (-) Molekulare Immunologie und Gentherapie (26) Protein Production and Characterization (1) Proteom Dynamik (1) Proteomics (2) Strukturbiologie Membran-assoziierter Prozesse (3) Systembiologie von Gen-regulatorischen Elementen (1) Transgenics (1) Translational Bioinformatics (3) Translationale Tumorimmunologie (1) Tumorgenetik und zelluläre Stressantworten (1) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) (-) 2004 (8) 2005 (10) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) (-) 2015 (3) 2016 (4) 2017 (6) 2018 (4) (-) 2019 (6) 2021 (4) 2022 (6) (-) 2023 (4) 2024 (2) 26 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Molekulare Immunologie und Gentherapie 20042011201520192023 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein 01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto 01. August 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster 01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 01. Januar 2004 / Nat Immunol A cancer immunosurveillance controversy Z.H. Qin T. Blankenstein 01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling 01. Januar 2004 / J Immunol Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18 T.H. Wu C.N. Pabin Z.H. Qin T. Blankenstein M. Philip J. Dignam K. Schreiber H. Schreiber 23. Januar 2004 The role of inflammation for tumour growth and tumour suppression T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein
01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto
01. August 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster
01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling
01. Januar 2004 / J Immunol Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18 T.H. Wu C.N. Pabin Z.H. Qin T. Blankenstein M. Philip J. Dignam K. Schreiber H. Schreiber